Timeline Entry
In 1909 at Frankfurt's Georg-Speyer-Haus, Japanese bacteriologist Sahachiro Hata found that an arsenical compound made by chemist Alfred Bertheim in Paul Ehrlich's research programme acted against syphilis in experimentally infected rabbits. Publicly reported and introduced by Hoechst in 1910 as Salvarsan, “compound 606” became one of the earliest widely adopted synthetic antimicrobial treatments. [1] [2] [3]
Its importance was methodological as well as therapeutic: related chemicals were synthesized, screened in disease models, manufactured at scale, and tested in clinics. Yet Salvarsan was arsenical, technically demanding to give, and less reliably curative than its early “magic bullet” reputation implied.
Historical Significance
Syphilis is a long, staged infection caused by Treponema pallidum. Before 1910, physicians used mercury, iodides, and other regimens that could be prolonged, toxic, and uncertain in effect. The 1905 identification of the spirochaete by Fritz Schaudinn and Erich Hoffmann, followed by the Wassermann serological test in 1906, gave laboratory investigators a named organism and clinicians a new—though imperfect—way to follow infection. Salvarsan joined these diagnostic changes to an experimental treatment programme. [1] [4] [10]
Ehrlich used “chemotherapy” for treating infection with chemicals and distinguished action on the parasite from injury to the host. Salvarsan fell well short of perfect selectivity, but its development made the comparison of antimicrobial effect and host toxicity part of a repeatable experimental strategy.
Early lesions could improve dramatically, but disappearance of symptoms was not the same as eradication of a systemic infection. Relapse and late disease remained concerns, so physicians repeated arsenical doses and often combined them with mercury or, later, bismuth. Salvarsan expanded therapeutic possibility; it did not make syphilis simple to cure. [4] [6] [10]
The Georg-Speyer-Haus and Ehrlich's Institute for Experimental Therapy provided research infrastructure; Bertheim and other chemists supplied compounds; Hata performed biological testing; clinicians assessed patients; and Hoechst manufactured and distributed the product. The drug was a networked institutional achievement, not one man's isolated discovery. [1] [2]
Chronology
Work on Salvarsan grew from experiments against trypanosomes, the parasites responsible for African sleeping sickness. Atoxyl, an existing arsenical, offered activity but could damage the optic nerve. Ehrlich and Bertheim clarified its chemistry and synthesized related organoarsenic compounds in search of a better balance between effect and toxicity. Bertheim made compound 606 in 1907; according to later accounts, an initial test judged it inactive, so it was set aside. [1] [3]
When Hata joined the Frankfurt laboratory, he systematically retested the arsenicals in rabbits infected with T. pallidum and identified 606's antisyphilitic action in 1909. Hata's role was therefore not merely assisting Ehrlich: his bacteriological technique and judgement supplied the decisive evidence, while Bertheim's synthesis made the test possible. Ehrlich and Hata's 1910 monograph gathered the animal studies with reports from several clinical sites and diseases; it is a record of their programme, not an independent evaluation of it. [2] [5]
“606” was a laboratory sequence number. It should not be read as 605 failed human trials, and it does not by itself assign discovery to a single person. [1] [2]
At the Bedside
Salvarsan arrived as a powder rather than a ready-to-use injection. A surviving kit contains a vial, crucible, litmus paper, and instruction sheets—material evidence that the medicine's performance depended on trained preparation as well as its nominal formula. The solution had to be made with suitable sterile water, alkalinised, protected from deterioration, and administered with care. [6] [7]
Arsenical toxicity was real, but contemporaries also blamed degraded solutions, contaminated water, manufacturing impurities, excessive doses, technique, or patients' underlying disease. Reports of serious injury and death generated controversy. The evidence did not support the reassuring claim that careful technique made the drug harmless, nor the opposite claim that every post-injection illness had one cause. [4] [8]
Wilhelm Wechselmann's 1911 clinical book, introduced by Ehrlich, documents early technique, case experience, reactions, and enthusiasm. It is valuable testimony from a clinician participating in Salvarsan's adoption, but its uncontrolled cases and advocacy cannot establish efficacy or safety by present-day trial standards. Recurrence over months mattered more than rapid clearing of visible lesions. [6]
The phrase compresses a complicated regimen into a heroic discovery story. Salvarsan was pathogen-directed, but it required repeated clinical labour, laboratory testing, and reliable manufacture. It also worked poorly for some late manifestations, including neurosyphilis, and did not fully displace mercury-based treatment. [4]
Institutions and Patients
Syphilis treatment was entangled with secrecy, sexual morality, and the period category “venereal disease.” A medicine that needed injections and serial assessment strengthened the case for specialist services, but it did not remove stigma or guarantee access. Patients needed a clinic, a trained practitioner, laboratory support, time for repeated visits, and a dependable supply of an imported or licensed product. [4]
Britain provides one documented example rather than a universal model. During the First World War and after the Royal Commission on Venereal Diseases, Salvarsan helped make treatment central to policy. By the end of 1917, 118 new clinics had opened and about 204,000 patients had been evaluated. Historians argue that the drug's effect on specialist venereology and public-health provision was in some respects more durable than its imperfect clinical performance. Other countries adopted and regulated arsenicals through their own medical, commercial, and political systems. [4]
Later Reputation
Some accounts call Salvarsan the first antibiotic; others reserve “antibiotic” for substances produced by microorganisms and describe it as a synthetic antimicrobial or chemotherapeutic agent. The narrower wording avoids a false priority claim while preserving what was novel: systematic synthesis and biological screening for a specific infection. [1] [2]
The familiar historical structural formula represented what Ehrlich and his contemporaries thought they had made. Modern mass spectrometry found that Salvarsan was a mixture of cyclic arsenic-containing species, and variable synthesis could introduce impurities. Later chemistry therefore complicates the idea of compound 606 as one perfectly defined molecule. [8]
Salvarsan and Neosalvarsan are obsolete. Current clinical guidance treats syphilis according to its stage and manifestations; parenteral penicillin G is the preferred drug for all stages. This modern comparison clarifies the historical limit without turning the entry into treatment advice. [9]
Reading Path
Read this entry with Paul Ehrlich, Penicillin, 1928, History of Antibiotics and Penicillin, and History of Pharmacy and Apothecaries.
References
Pharmacology 82, no. 3: 171–179. A scholarly overview of Ehrlich's research system, the 1909–10 chronology, clinical circulation, and Neosalvarsan. Full text and DOI 10.1159/000149583.
Journal of Infection and Chemotherapy 29, no. 5: 546–548. A review centred on Hata's training, experimental work, and frequently compressed role in the Salvarsan story. PubMed record and DOI 10.1016/j.jiac.2023.02.010.
A Smithsonian collection record identifying Bertheim's 1907 synthesis, Hata's 1909 finding, and the commercial material preserved in a labelled vial. Collection record.
Sexually Transmitted Infections 91, no. 1: 69–70. A focused historical analysis of incomplete efficacy, toxicity, specialist venereology, and British clinic provision. Full text and DOI 10.1136/sextrans-2014-051780.
The investigators' German monograph assembling animal experiments and contributions from clinical sites. It is a primary source for their programme and claims, not an independent modern assessment. Digitised edition and catalogue record.
An English translation of an early clinician's account, with an introduction by Ehrlich. Useful for contemporary technique, case observation, and advocacy, but limited by its uncontrolled evidence and proximity to the drug's promoters. Digitised edition, LCCN 11005201.
A c. 1909–12 kit containing the vial, crucible, litmus paper, and instructions needed to turn the manufactured powder into a clinical preparation. Collection record.
Angewandte Chemie International Edition 44, no. 6: 941–944. Modern chemical analysis of Salvarsan's cyclic species and the impurity problem. PubMed record and DOI 10.1002/anie.200461471.
Used only to distinguish the historical arsenical regimen from current clinical practice. Current guidance.
Revista Española de Quimioterapia 31, no. 6: 485–492. A review of the changing roles of mercury, iodides, Salvarsan, bismuth, and penicillin. PubMed record, PMCID PMC6254479.